Background:Apoptosis signal-regulating kinase 1(ASK1)is a MAP3K kinase in the MAPK signaling pathway activated by stressors and triggers downstream biological effects such as inflammation and apoptosis;therefore,inhib...Background:Apoptosis signal-regulating kinase 1(ASK1)is a MAP3K kinase in the MAPK signaling pathway activated by stressors and triggers downstream biological effects such as inflammation and apoptosis;therefore,inhibition of ASK1 kinase ac-tivity can protect cells from pathological injury.In this study,we designed and synthe-sized a novel selective ASK1 inhibitor,CS17919,and investigated its pharmacological effects in various animal models of metabolic injury.Methods:First,we validated the ability of CS17919 to inhibit ASK1 in vitro and then tested the safety profile of CS17919 in cell lines compared with Selonsertib(GS-4997),a phase III ASK1 inhibitor.We then conducted pharmacokinetic(PK)studies in mice.Finally,we tested the in vivo efficacy of CS17919 in murine models of chronic kidney disease(CKD)and non-alcoholic steatohepatitis(NASH).Results:Compared to GS-4997,CS17919 demonstrated comparable inhibition of ASK1 in vitro,exhibited lower toxicity,and provided greater protection in palmitic acid-treated LO2 cells.CS17919 also showed pronounced pharmacokinetic prop-erties such as a high plasma concentration.In the unilateral ureteral obstruction model(UUO),CS17919 and GS-4997 preserved kidney function and showed a non-significant tendency to alleviate kidney fibrosis.In the diabetic kidney disease(DKD)model,CS17919 significantly improved serum creatinine and glomerular sclerosis.In the NASH model,the combination of CS17919 and a THRβagonist(CS27109)was found to significantly improve liver inflammation and substantially reduced liver fibrosis.Conclusions:CS17919 showed cell protective,anti-inflammatory,and antifibrotic ef-fects in vitro and in vivo,suggesting its therapeutic potential for metabolic-related kidney and liver diseases.展开更多
目的通过检测ASK1和PRKCD在单核细胞分化过程中的表达变化,探索其在门静脉高压症(PH)脾亢脾脏巨噬细胞(MΦ)功能变化中所起的作用。方法采用佛波酯诱导U937分化成为巨噬细胞样细胞,q-PCR检测不同分化阶段ASK1和PRKCD m RNA的表达,Wester...目的通过检测ASK1和PRKCD在单核细胞分化过程中的表达变化,探索其在门静脉高压症(PH)脾亢脾脏巨噬细胞(MΦ)功能变化中所起的作用。方法采用佛波酯诱导U937分化成为巨噬细胞样细胞,q-PCR检测不同分化阶段ASK1和PRKCD m RNA的表达,Western Blot检测诱导前后ASK1和PRKCD蛋白表达水平变化,ELISA法检测细胞分化过程中与吞噬功能相关的细胞因子IL-10和TNF-α的分泌情况,鸡红细胞吞噬试验鉴定诱导后细胞功能。结果随着PMA诱导U937细胞时间延长,ASK1和PRKCD基因表达水平下降,TNF-α的分泌量逐渐增加,而IL-10在诱导后24 h达到最大分泌量,随后又呈下降趋势;Western Blot结果显示,ASK1及p-ASK1蛋白表达水平较诱导前均显著上升,PRKCD及p-PRKCD蛋白表达水平显著下降;吞噬实验结果显示,诱导后的细胞具有一定的吞噬功能。结论在PMA诱导的U937细胞向单核细胞分化过程中,ASK1蛋白表达上调,PRKCD蛋白表达下调,与脾亢脾Mφ一致,并导致Mφ活性增强。展开更多
文摘Background:Apoptosis signal-regulating kinase 1(ASK1)is a MAP3K kinase in the MAPK signaling pathway activated by stressors and triggers downstream biological effects such as inflammation and apoptosis;therefore,inhibition of ASK1 kinase ac-tivity can protect cells from pathological injury.In this study,we designed and synthe-sized a novel selective ASK1 inhibitor,CS17919,and investigated its pharmacological effects in various animal models of metabolic injury.Methods:First,we validated the ability of CS17919 to inhibit ASK1 in vitro and then tested the safety profile of CS17919 in cell lines compared with Selonsertib(GS-4997),a phase III ASK1 inhibitor.We then conducted pharmacokinetic(PK)studies in mice.Finally,we tested the in vivo efficacy of CS17919 in murine models of chronic kidney disease(CKD)and non-alcoholic steatohepatitis(NASH).Results:Compared to GS-4997,CS17919 demonstrated comparable inhibition of ASK1 in vitro,exhibited lower toxicity,and provided greater protection in palmitic acid-treated LO2 cells.CS17919 also showed pronounced pharmacokinetic prop-erties such as a high plasma concentration.In the unilateral ureteral obstruction model(UUO),CS17919 and GS-4997 preserved kidney function and showed a non-significant tendency to alleviate kidney fibrosis.In the diabetic kidney disease(DKD)model,CS17919 significantly improved serum creatinine and glomerular sclerosis.In the NASH model,the combination of CS17919 and a THRβagonist(CS27109)was found to significantly improve liver inflammation and substantially reduced liver fibrosis.Conclusions:CS17919 showed cell protective,anti-inflammatory,and antifibrotic ef-fects in vitro and in vivo,suggesting its therapeutic potential for metabolic-related kidney and liver diseases.
